Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: Integrating vascular dysfunction

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 12, 2011, Pages 1347-1353

  Tsioufis, Costas ^a,b   Aggelis, Athanasios ^b   Dimitriadis, Kyriakos ^b   Thomopoulos, Costas ^b   Kasiakogias, Alexandros ^b   Tzamou, Vanessa ^b   Kyvelou, Stella Maria ^b   Mikhailidis, Dimitri P ^c   Papademetriou, Vasilios ^d   Stefanadis, Christodoulos ^b  

^a First Cardiology Clinic ^*  (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

albuminuria; asymmetric dimethylarginine; hypertension; osteoprotegerin

Indexed keywords

ALBUMIN; CREATININE; N(G),N(G) DIMETHYLARGININE; OSTEOPROTEGERIN;

ADULT; ALBUMINURIA; ARTICLE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PREDICTOR VARIABLE; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

EID: 83655202795     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.642868     Document Type: Article

References (37)

1. Kudlacek S, Schneider B, Woloszczuk W, et al. Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003;32:681-6 (Pubitemid 37303940)
2. Speer G, Fekete BC, El Hadj Othmane T, et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 2008;23:3256-62
3. Stepien E, Wypasek E, Stopyra K, et al. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem 2011;44:826-31
4. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-80 (Pubitemid 38625393)
5. Kurnatowska I, Grzelak P, Kaczmarska M, et al. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract 2011;117:297-304
6. Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008;51:627-33 (Pubitemid 351193104)
7. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4 (Pubitemid 34988634)
8. Kim BJ, Sung KC, Kim BS, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and c reactive protein. Clin Sci (Lond) 2005;108:237-43
9. Cooke JP. Asymmetrical dimethylargine. The uber marker? Circulation 2004;109:1813-19
10. Zoccali C. Asymmetrical dimethylargine (ADMA): A cardiovascular and renal risk factor on the move. J Hypertens 2006;24:611-19
11. Boger RH, Zoccali C. ADMA: A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 2003;4:23-8 (Pubitemid 38234491)
12. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-9
13. Kielstein JT, Bode-Boger SM, Frolich JC, et al. Asymmetric dimethylarginine, blood pressure and renal perfusion in elderly subjects. Circulation 2003;107:1891-5 (Pubitemid 36444130)
14. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001;358:2113-17 (Pubitemid 34094901)
15. Palloshi A, Fragasso G, Piatti P, et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise test and normal coronary arteries. Am. J. Cardiol 2004;93:930-5
16. Takiushi S, Fujii H, Kamide K, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am. J. Hypertens 2004;17:802-8 (Pubitemid 39201096)
17. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518-23 (Pubitemid 41040296)
18. Furuki K, Adachi H, Matsuoka H, et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. An epidemiological study. Atherosclerosis 2007;191:206-10 (Pubitemid 46227419)
19. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002;62:339-45 (Pubitemid 34754080)
20. Krzyzanowska K, Mittermayer F, Shnawa N, et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med 2007;24:81-6 (Pubitemid 46103075)
21. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006;70:781-7 (Pubitemid 44215355)
22. Tsioufis C, Dimitriadis K, Andrikou E, et al. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: A cross-sectional study. Am. J. Kidney Dis 2010;55:1050-9
23. Tsioufis C, Dimitriadis K, Antoniadis D, et al. Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am. J. Hypertens 2004;17:470-6 (Pubitemid 38529972)
24. Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am. J. Cardiol 2005;96:946-51 (Pubitemid 41362518)
25. Tsioufis C, Dimitriadis K,Taxiarchou E, et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am. J. Hypertens 2006;19:462-6
26. Xiang GD, Pu JH, Zhao LS, et al. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med 2009;26:397-403
27. Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149:39-42 (Pubitemid 36874202)
28. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007;25:1105-87
29. Tsioufis C, Stefanadis C, Antoniadis D, et al. Absence of any significant effects of circadian blood pressure variations on carotid artery elastic properties in essential hypertensive subjects. J Hum Hypertens 2000;14:813-18 (Pubitemid 32015834)
30. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am. J. Kidney Dis 2002;39:S1-S246
31. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricular dimensions by two-dimensional echocardiography. American Society of Echocardiography Committee on standards, subcommittee on quantitation of the two-dimensional echocardiograms. J Am Soc Echocardiogr 1989;2:358-67
32. Lib W, Gona P, Larson MG, et al. Biomarkers of the osteoprotegerin pathway clinical correlates, subclinical disease, incident cardiovascular disease and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849-54
33. Caidahl K, Ueland T, Aukrust P. Osteoprotegerin: A biomarker with many faces. Arterioscler Thromb Vasc Biol 2010;30:1684-6
34. Ali Z, Ellington AA, Mosley TH Jr, Kullo IJ. Association of serum osteoprotegerin with ankle-brachial index and urine albumin: Creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis 2009;206:575-80
35. Noheria A, Mosley TH, Kullo IJ. Association of serum osteoprotegerin with left ventricular mass in African-American adults with hypertension. Am. J. Hypertens 2010;23:767-74
36. Omland T, Drazner MH, Ueland T, et al. Plasma osteoprotegerin levels in the general population: Relation to indices of left ventricular structure and function. Hypertension 2007;49:1392-8 (Pubitemid 46809385)
37. Verdecchia P, Schillaci G, Borgioni C, et al. Ambulatory pulse pressure: A potent predictor of total cardiovascular risk in hypertension. Hypertension 1998;32:983-8 (Pubitemid 29001424)